Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b
| Autor: | Elizabeth A. Chlipala, Ji I Lee, Stephen P. Eisenberg, Mary S. Rosendahl, Jacquelyn D. Brown, George N. Cox, Daniel H. Doherty |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Immunology Lysine Antineoplastic Agents Polyethylene glycol Pharmacology Polyethylene Glycols chemistry.chemical_compound Mice In vivo Virology PEG ratio Animals Humans Cysteine Cell Proliferation chemistry.chemical_classification Dose-Response Relationship Drug Research Reports Cell Biology Interferon-beta Xenograft Model Antitumor Assays In vitro Recombinant Proteins Amino acid Rats chemistry Biochemistry Amino Acid Substitution PEGylation Interferon beta-1b |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 33(12) |
| ISSN: | 1557-7465 |
| Popis: | Interferon beta (IFN-β) is widely used to ameliorate disease progression in patients with Multiple Sclerosis. IFN-β has a short half-life in humans, necessitating frequent administration for optimum effectiveness. Covalent modification of IFN-β with polyethylene glycol (PEG) improves the pharmacokinetic properties of the protein, but can adversely affect the protein's in vitro bioactivity. Random modification of lysine residues in IFN-β with amine-reactive PEGs decreased the in vitro bioactivity of the protein 50-fold, presumably due to modification of lysine residues near critical receptor binding sites. PEGylated IFN-β proteins that retained high in vitro bioactivity could be obtained by selective modification of the N-terminus of the protein with PEG. Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-β) to identify several additional amino acid positions where PEG can be attached to IFN-β without appreciable loss of in vitro bioactivity. Unexpectedly, we found that most of the PEG-IFN-β analogs showed 11- to 78-fold improved in vitro bioactivities relative to their unPEGylated parent proteins and to IFN-β-1b. In vivo studies showed that a lead PEG-IFN-β protein had improved pharmacokinetic properties compared to IFN-β and was significantly more effective than IFN-β at inhibiting growth of a human tumor xenograft in athymic mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|